The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. PROs provide unique information on the impact of a medical condition and its treatment from the patient's perspective; therefore, PROs can be included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. This review first discusses examples of how PRO endpoints have added value to clinical trial interpretation. Second, it describes the problems with current practices in designing, implementing, and reporting PRO studies, and how these problems may be addressed by complying with guidance for protocol development, selecting appropriate PRO measures to match clinically motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and interpreting PRO data, and transparently reporting PRO findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The weaRAble-PRO study administered a selection of validated PRO measures for RA in complement to bespoke digital PRO assessments—that are validated in clinical trials”
From Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580 · cited 2×
“21,22 The PRO endpoints led to regulatory approval of mitoxantrone for this indication and wide implementation in the clinic.”
InfluentialSelf-citationReporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group, F. T. (2013) · JAMA · doi:10.1001/jama.2013.879 · Cited by 1,386 · cited 2×
“This work informed the development of a CONSORT-PRO Extension (Consolidated Standards of Reporting Trials), which can be considered the minimum reporting items for PRO endpoints (primary or key secondary) in RCTs. 73 CONSORT-PRO consists of 14 items, five of which were newly developed PRO-specific reporting recommenda…”
Self-citationReducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319 · cited 1×
“However, the issue of non-reporting of PROs is emerging and requires attention, as it is unethical to waste the funding, resources, and patients’ efforts expended in PRO data collection.(71)”
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 2×
“In oncology, for example, the American Society of Clinical Oncology (ASCO)(10) and European Society for Medical Oncology (ESMO)(11) have proposed standardized approaches to evaluate clinical trial results by using scores to evaluate the Magnitude of Clinical Benefit (ESMO MCB) or the Net Health Benefit (ASCO), which i…”
Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M. T., and the SPIRIT-PRO Group, Hunn, A., Bottomley, A., Regnault, A., et al. (2018) · JAMA · doi:10.1001/jama.2017.21903 · Cited by 814 · cited 5×
“A second review examined the PRO content of 26 protocols of Phase III international, ovarian cancer trials published between 2000 and 2016 against a list of PRO-specific items that would eventually inform the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension.(29,30) Of the 26 tr…”
InfluentialSelf-citation
Research works printed but not linked: 2
- [15]Food and Drug Administration Ovarian Cancer Endpoints Workshop April 26, 2006, Meeting Summary 2006 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Developmen-tResources/CancerDrugs/ucm094598.pdf accessed 09 August 2016 https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf Accessed 14 August 2017.v
- [56]Mercieca-Bebber R Palmer MJ Brundage M Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review BMJ Open 2016 6 6 e010938 PMC4916640 27311907
Cited by
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Campbell, R., Ju, A., King, M. T., & Rutherford, C. (2022) · Quality of Life Research · doi:10.1007/s11136-021-03003-z · Cited by 188
Self-citationRivera, S. C., Kyte, D. G., Aiyegbusi, O. L., Slade, A. L., McMullan, C., & Calvert, M. J. (2019) · Health and Quality of Life Outcomes · doi:10.1186/s12955-019-1220-z · Cited by 192
“metrics were drew upon the ‘pathways to research impact’ framework [6] Rivera et al.”
BackgroundMethodInfluentialSelf-citationInterventions for the management of long covid (post-covid condition): living systematic review
Zeraatkar, D., Ling, M., Kirsh, S., Jassal, T., Shahab, M., Movahed, H., Talukdar, J. R., Walch, A., Chakraborty, S. P., Turner, T., et al. (2024) · BMJ · doi:10.1136/bmj-2024-081318 · Cited by 185
“135-137 Implications Our findings suggest that offering patients with long covid a programme of CBT or a programme of physical and mental health rehabilitation will probably improve symptoms.”
Calvert, M., King, M., Mercieca-Bebber, R., Aiyegbusi, O., Kyte, D., Slade, A., Chan, A.-W., Basch, E., Bell, J., Bennett, A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045105 · Cited by 144
Self-citationBeaudart, C., Alcázar, J., Aprahamian, I., Batsis, J. A., Yamada, Y., Prado, C. M. M., Reginster, J., Sánchez‐Rodríguez, D., Lim, W. S., Sim, M., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-02995-9 · Cited by 194
“This transition has been driven by various stakeholders, including clinicians, pharmaceutical industries, and regulatory agencies, all of whom have come to recognize the importance of integrating patient-reported outcomes (PROs) alongside traditional biomarkers of health improvement [40, 41].”
Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
Haslam, A., Herrera-Perez, D., Gill, J., & Prasad, V. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.0363 · Cited by 103
Knapp, A., Harst, L., Hager, S., Schmitt, J. M., & Scheibe, M. (2021) · Journal of Medical Internet Research · doi:10.2196/30042 · Cited by 114
“This could be caused by the wider recognition and implementation of PROMs and PREMs [50,51], as can be seen in Figure 7, where the growth rate of studies using PROMs and PREMs is far higher than the growth rate of telemedicine papers in MEDLINE.”
Gresham, G. K., Meinert, J. L., Gresham, A. G., & Meinert, C. L. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.14682 · Cited by 94
Reginster, J., Beaudart, C., Al‐Daghri, N. M., Avouac, B. P., Bauer, J. M., Bere, N., Bruyère, O., Cerreta, F., Cesari, M., Rosa, M. M., et al. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01663-4 · Cited by 96
“), clinicians and patients as valuable tools to be used in clinical trials to ensure the impact of a clinical intervention is comprehensively assessed [36].”
BackgroundFeatures of Marfan syndrome not listed in the Ghent nosology – the dark side of the disease
Kodolitsch, Y. V., Demolder, A., Girdauskas, E., Kaemmerer, H. M., Kornhuber, K., Mosquera, L. M., Morris, S. A., Neptune, E., Pyeritz, R. E., Rand‐Hendriksen, S., et al. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1704625 · Cited by 86
Balachandran, A. T., Steele, J., Angielczyk, D., Belio, M., Schoenfeld, B. J., Quiles, N., Askin, N., & Abou-Setta, A. M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11623 · Cited by 70
Crossnohere, N. L., Brundage, M., Calvert, M., King, M. T., Reeve, B. B., Thorner, E. D., Wu, A. W., & Snyder, C. F. (2020) · Quality of Life Research · doi:10.1007/s11136-020-02625-z · Cited by 77
Self-citationMoons, P., Norekvål, T. M., Arbelo, E., Borregaard, B., Casadei, B., Cosyns, B., Cowie, M., Fitzsimons, D., Fraser, A. G., Jaarsma, T., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad514 · Cited by 79
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., Atri, A., & Cummings, J. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00984-y · Cited by 71
“Finally, regulatory agencies encourage PRO assessments in clinical studies [52].”
BackgroundWeiss, J., Goldschmidt, J. H., Andric, Z. G., Dragnev, K. H., Gwaltney, C. J., Skaltsa, K., Pritchett, Y., Antal, J. M., Morris, S. R., & Daniel, D. B. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.010 · Cited by 74
Creagh, A. P., Hamy, V., Yuan, H., Mertes, G., Tomlinson, R., Chen, W.-H., Williams, R., Llop, C., Yee, C., Duh, M. S., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01013-y · Cited by 64
Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000–2020
Gresham, G. K., Meinert, J. L., Gresham, A. G., Piantadosi, S., & Meinert, C. L. (2022) · Trials · doi:10.1186/s13063-022-06569-2 · Cited by 66
Creagh, A. P., Hamy, V., Yuan, H., Mertes, G., Tomlinson, R., Chen, W.-H., Williams, R., Llop, C., Yee, C., Duh, M. S., et al. (2022) · doi:10.1101/2022.11.18.22282305 · Cited by 64
Puthucheary, Z., Gensichen, J. S., Cakiroglu, S. A., Cashmore, R., Edbrooke, L., Heintze, C., Neumann, K., Wollersheim, T., Denehy, L., & Schmidt, K. F. R. (2020) · Critical Care · doi:10.1186/s13054-020-03275-w · Cited by 60
McGregor, G., Powell, R., Kimani, P., & Underwood, M. R. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-036089 · Cited by 73
Gilbert, A., Piccinin, C., Velikova, G., Grøenvold, M., Kuliś, D., Blazeby, J. M., & Bottomley, A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02017 · Cited by 56
“By providing unique insights into domains that are difficult to assess through biomedical outcomes and clinician ratings alone (eg,, fatigue and pain), PROs provide a more complete, patient-centered picture of the impact of disease and treatment.(5)”
BackgroundRubino, D., Bjorner, J. B., Rathor, N., Sharma, A. M., von Huth Smith, L., Wharton, S., Wadden, T., Zeuthen, N., & Kolotkin, R. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15620 · Cited by 56
Assessment of long-term psychosocial outcomes in anti-NMDA receptor encephalitis
Blum, R. A., Tomlinson, A. R., Jetté, N., Kwon, C., Easton, A., & Yeshokumar, A. K. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107088 · Cited by 58
Rivera, S. C., McMullan, C., Jones, L. L., Kyte, D. G., Slade, A. L., & Calvert, M. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00219-4 · Cited by 56
Self-citationAddario, B. J., Geißler, J., Horn, M. K., Krebs, L. U., Maskens, D. A., Oliver, K. R., Plate, A., Schwartz, E. C., & Willmarth, N. E. (2019) · Health Expectations · doi:10.1111/hex.12997 · Cited by 54
Gnanasakthy, A., Norcross, L., DeMuro, C., & Carson, R. T. (2021) · Value in Health · doi:10.1016/j.jval.2021.10.006 · Cited by 49
Curigliano, G., Dunton, K., Rosenlund, M., Janek, M., Cathcart, J., Liu, Y., Fasching, P. A., & Iwata, H. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.516 · Cited by 52
Patient-reported outcome measures for life engagement in mental health: a systematic review
McIntyre, R. S., Ismail, Z., Watling, C. P., Weiss, C., Meehan, S. R., Musingarimi, P., & Thase, M. E. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00468-5 · Cited by 48
“Patient-reported outcomes (PROs) can be used in clinical research to capture outcomes that are meaningful to the patient, in a manner that is standardized across the trial population [1, 2].”
BackgroundMediavilla, R., Felez-Nobrega, M., McGreevy, K. R., Monistrol-Mula, A., Bravo-Ortiz, M.-F., Bayón, C., Giné-Vázquez, I., Villaescusa, R., Muñoz-Sanjosé, A., Aguilar-Ortiz, S., et al. (2023) · BMJ Mental Health · doi:10.1136/bmjment-2023-300697 · Cited by 47
Serper, M., Parikh, N. D., Thiele, G., Ovchinsky, N., Mehta, S., Kuo, A., Ho, C., Kanwal, F., Volk, M., Asrani, S. K., et al. (2022) · Hepatology · doi:10.1002/hep.32313 · Cited by 46
“Second, PROs may play a role in guiding decision- making regarding treatment selection and stopping rules.[3] Finally, PROs can be used to define treatment effectiveness for regulatory purposes.”
Polhemus, A. M., Bergquist, R., de Basea, M. B., Brittain, G., Buttery, S. C., Chynkiamis, N., Costa, G. D., Delgado‐Ortiz, L., Demeyer, H., Emmert, K., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038704 · Cited by 42
Nigusso, F. T., & Mavhandu-Mudzusi, A. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01702-2 · Cited by 43
Denadai, R., Chou, P., Su, Y., Lo, C.-C., Lin, H., Ho, C.-T., & Lo, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060909 · Cited by 51
Fehm, T. N., Cottone, F., Dunton, K., André, F., Krop, I. E., Park, Y. H., Laurentiis, M. D., Miyoshi, Y., Armstrong, A. C., Borrego, M. R., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00128-1 · Cited by 45
Bellino, S., & Salvia, A. L. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00478-2 · Cited by 48
“…standardised approaches to evaluate clinical trial results by using scores to evaluate the Mag-nitude of Clinical Benefit Scale (ESMO) or Net Health Benefit Score (ASCO), which include evidence regarding improved or delayed deterioration in HRQOL in addition to survival endpoints and toxicity [6].”
MethodVerma, S., Leiter, L. A., Mangla, K. K., NIELSEN, N. F., Hansen, Y., & Bonaca, M. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01606-6 · Cited by 57
Tarawneh, R. M., & Pankratz, V. S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01412-z · Cited by 51
“Measuring PROs, that are validated for use in clinical trials and appropriate for disease stage, is encouraged by regulatory agencies as they capture patient experience data which can inform long-term evaluations of clinical meaningfulness and safety [34, 36, 37].”
BackgroundKampmeier, T., Rehberg, S. W., Alsaleh, A. J. O., Schraag, S., Pham, J., & Westphal, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.01.008 · Cited by 40
Cheung, D. S. T., Takemura, N., Smith, R. D., Yeung, W. F., Xu, X., Ng, A. Y. M., Lee, S. F., & Lin, C. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.06.036 · Cited by 45
Teixeira, M. M., Borges, F. C., Ferreira, P. B. S., Rocha, J. P., Sepodes, B. M. N., & Torre, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.968272 · Cited by 48
Culakova, E., Mohile, S. G., Peppone, L. J., Ramsdale, E. E., Mohamed, M., Xu, H., Wells, M., Tylock, R. G., Java, J., Loh, K. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00738 · Cited by 41
“The selected time intervals were a limitation since the PRO-CTAE items were not collected weekly, and thus may not have captured the period when symptomatic toxicities were present or most severe.(61) The study was not fully powered for the outcome of symptomatic toxicity.”
BackgroundVenderbos, L. D. F., Deschamps, A., Dowling, J., Carl, E.-G., Remmers, S., van Poppel, H., & Roobol, M. J. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.11.002 · Cited by 38
Wang, A. T., Panayi, A. C., Fischer, S., Diehm, Y. F., Tapking, C., Hundeshagen, G., Kneser, U., Mastroianni, M., Pomahač, B., & Haug, V. (2022) · Aesthetic Surgery Journal · doi:10.1093/asj/sjac293 · Cited by 37
Guardado, S., Karampela, M., Isomursu, M., & Grundstrom, C. (2024) · Journal of Medical Internet Research · doi:10.2196/49320 · Cited by 43
Lee, J. H., Kong, S., Shin, S., Lee, G., Kim, H. K., Shim, Y. M., Cho, J., Kang, D., & Park, H. Y. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.34180 · Cited by 46
Janne, P. A., Goto, Y., Kubo, T., Ninomiya, K., Kim, S., Planchard, D., Ahn, M., Smit, E. F., Langen, A. J. D., Pérol, M., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.07.129 · Cited by 35
Yu, H., Yu, Q., Nie, Y., Xu, W., Pu, Y., Dai, W., Wei, X., & Shi, Q. (2021) · Journal of Medical Internet Research · doi:10.2196/28915 · Cited by 39
Stauder, R., Lambert, J., Desruol‐Allardin, S., Savre, I., Gaugler, L., Stojkov, I., Siebert, U., & Chevrou‐Séverac, H. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13389 · Cited by 36
Pape, L. M., Adriaanse, M. C., Kol, J., van Straten, A., & van Meijel, B. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03854-x · Cited by 39
“PROs are valuable outcomes as they represent topics that are meaningful to patients and provide insight on the impact of interventions from the patient’s perspective [17, 18].”
BackgroundCochlea-Implantation: Konzept, Therapieergebnisse und Lebensqualität
Lenarz, T., Büchner, A., & Illg, A. (2022) · Laryngo-Rhino-Otologie · doi:10.1055/a-1731-9321 · Cited by 46
“[134] Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M.”
BackgroundTomasi, C., Abrahamsson, K. H., & Apatzidou, D. A. (2023) · Periodontology 2000 · doi:10.1111/prd.12485 · Cited by 48
Guidelines for the development and validation of patient-reported outcome measures: a scoping review
Jung, A., Challoumas, D., Pagels, L., Armijo-Olivo, S. L., Braun, T., & Luedtke, K. (2024) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2023-112681 · Cited by 43
Shogren, K. A., Dean, E. E., Burke, K. M., Raley, S. K., & Taylor, J. L. (2021) · Intellectual and developmental disabilities · doi:10.1352/1934-9556-59.1.7 · Cited by 35
Weißbuch Citizen Science Strategie 2030 für DeutschlandPreprint
Bonn, A., Brink, W., Hecker, S., Herrmann, T. M., Liedtke, C., Premke-Kraus, M., Voigt‐Heucke, S. L., von Gönner, J., Altmann, C. S., Bauhus, W., et al. (2021) · SocArXiv (OSF Preprints) · doi:10.31235/osf.io/ew4uk · Cited by 56
Determining minimal important change for the thyroid related quality of life questionnaire ThyPRO
Nordqvist, S. F., Boesen, V. B., Rasmussen, Å. K., Feldt-Rasmussen, U., Hegedüs, L., Bonnema, S. J., Cramon, P. K., Watt, T., Groenvold, M., & Bjorner, J. B. (2021) · Endocrine Connections · doi:10.1530/ec-21-0026 · Cited by 31
Symptoms of dry eye related to the relative humidity of living places
Martín, R. (2023) · Contact Lens and Anterior Eye · doi:10.1016/j.clae.2023.101865 · Cited by 31
Sim, J.-A., Huang, X., Horan, M. R., Baker, J. N., & Huang, I. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2322664 · Cited by 40
“Clinical trials increasingly incorporate PROs as primary or secondary endpoints [3].”
BackgroundFred Saad, C., Thiery-Vuillemin, A., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00498-3 · Cited by 34
Morita, A., Choon, S. E., Bachelez, H., Anadkat, M. J., Marrakchi, S., Zheng, M., Tsai, T., Turki, H., Hua, H., Rajeswari, S., et al. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00835-6 · Cited by 31
“the patients’ perspective, and PROs are considered an important factor by dermatologists when making treatment decisions in patients with psoriasis [19, 20].”
BackgroundAhmed, S., Barbera, L. C., Bartlett, S. J., Bebb, D. G., Brundage, M., Bryan, S., Cheung, W. Y., Coburn, N. G., Crump, T., Cuthbertson, L., et al. (2020) · Current Oncology · doi:10.3747/co.27.6399 · Cited by 31
Beaudart, C., Reginster, J., Thiyagarajan, J. A., Bautmans, I., Bauer, J. M., Burlet, N., Cesari, M., Cherubini, A., Cooper, C. C., Cruz-Jentoft, A. J., et al. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02438-3 · Cited by 31
Dias-Barbosa, C., Matos, R., Vernon, M., Carney, C. E., Krystal, A. D., & Puelles, J. (2020) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-020-00265-y · Cited by 29
Campelo, M. R. G., Lin, H. M., Zhu, Y., Pérol, M., Jahanzeb, M., Popat, S., Zhang, P., & Camidge, D. R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.03.005 · Cited by 30
Patient-Centered Core Impact Sets: What They are and Why We Need Them
Perfetto, E. M., Oehrlein, E. M., Love, T. R., Schoch, S. C., Kennedy, A., & Bright, J. L. (2022) · Patient · doi:10.1007/s40271-022-00583-x · Cited by 28
Wolters, P. L., Vranceanu, A., Thompson, H. L., Martin, S. C., Merker, V. L., Baldwin, A. M., Barnett, C., Koetsier, K. S., Hingtgen, C. M., Funes, C. J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012421 · Cited by 28
“The Federal Drug Administration, European Medicines Agency, and several professional oncology societies support the use of PRO measures in clinical trials and the development of standardized approaches and consensus-based guidance.(9,10) Harmonization of clinical outcome measures facilitates implementing multicenter s…”
BackgroundMethodWeszl, M., Rencz, F., & Brodszky, V. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01070-1 · Cited by 27
Murali, C. N., Cuthbertson, D. D., Slater, B. A., Nguyen, D. D., Turner, A., Harris, G. E., Sutton, V. R., Lee, B., Rauch, F., Glorieux, F. H., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0688-6 · Cited by 28
The use of patient reported outcome measures (PROMs) in palliative radiotherapy: A topical review
Oldenburger, E., Oldenburger, F. R., Coolbrandt, A., Isebaert, S. F., Neyens, I., Sevenants, A., Audenhove, C. V., & Haustermans, K. M. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.04.045 · Cited by 28
Self-Determination Assessment in Adults With and Without Intellectual Disability
Shogren, K. A., Rifenbark, G. G., & Hagiwara, M. (2021) · Intellectual and developmental disabilities · doi:10.1352/1934-9556-59.1.55 · Cited by 26
Beauchamp-Chalifour, P., Flexman, A. M., Street, J., Fisher, C. G., Ailon, T. T., Dvorak, M. F., Kwon, B. K., Paquette, S. J., Dea, N., & Charest-Morin, R. (2021) · Journal of Neurosurgery Spine · doi:10.3171/2021.2.spine201879 · Cited by 26
Parry, M. G., Skolarus, T. A., Nossiter, J., Sujenthiran, A., Morris, M., Cowling, T. E., Berry, B., Aggarwal, A. K., Payne, H. A., Cathcart, P. J., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15663 · Cited by 26
Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?
Giombi, F., Pace, G. M., Pirola, F., Cerasuolo, M., Ferreli, F., Mercante, G., Spriano, G., Canonica, G. W., Heffler, E., Ferri, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020730 · Cited by 25
Królikowska, A., Reichert, P., Senorski, E. H., Karlsson, J., Becker, R., & Prill, R. (2024) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1002/ksa.12334 · Cited by 25
Patient- and 3D morphometry-based nose outcomes after skeletofacial reconstruction
Denadai, R., Chou, P., Seo, H. J., Lonic, D., Lin, H., Pai, B. C.-J., & Lo, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-61233-6 · Cited by 25
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials
Coleman, R. L., Beck, J. T., Baranda, J. C., Jacobs, I. A., Smoyer, K. E., Lee, L. J., Askerova, Z., McGinnis, J. M., & Ganti, A. K. (2021) · Oncology · doi:10.1159/000514874 · Cited by 26
DENTAL PATIENT-REPORTED OUTCOMES IN ENDODONTICS - A NARRATIVE REVIEW
Nagendrababu, V., Vinothkumar, T. S., Karim, I. A. E., Rossi‐Fedele, G., Doğramacı, E. J., Dummer, P. M. H., & Duncan, H. F. (2022) · Journal of Evidence Based Dental Practice · doi:10.1016/j.jebdp.2022.101805 · Cited by 26
Garey, K. W., Dubberke, E. R., Guo, A. X., Harvey, A., Yang, M., García-Horton, V., Fillbrunn, M. K., Wang, H., Tillotson, G., Bancke, L. L., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad383 · Cited by 25
“Patient-reported outcomes are important, independent clinical trial end points that provide a multidimensional view on the benefits of a particular treatment on patients’ overall health that can inform clinical and regulatory decisions [24].”
BackgroundMontelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis
Mayoral, K., Lizano-Barrantes, C., Zamora, V., Pont, À., Miret, C., Barrufet, C., Caballero‐Rabasco, M. A., Praena-Crespo, M., Bercedo, A., Navarrete, L. V., et al. (2023) · European Respiratory Review · doi:10.1183/16000617.0124-2023 · Cited by 43
“…for noninclusion in the meta-analyses were results not being segregated for children and adults [59, 60, 64, 66, 67, 69, 72 – 74, 76 – 82], There is growing evidence that PROM results are frequently omitted and not reported, and data are presented with suboptimal reporting standards [88, 89].”
Low, G. M. I., Kiong, K. L., Amaku, R., Kruse, B. C., Zheng, G., Weber, R. S., & Lewis, C. M. (2020) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2020.102679 · Cited by 25
Kanu, C., Shinde, S., Chakladar, S., Dennehy, E. B., Weaver, T. E., Poon, J. L., & Malhotra, A. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106719 · Cited by 28
“Patient-reported outcome measures (PROMs) can provide important insights into patients’ perspectives on their health, well-being, and day-to-day functioning [23,24].”
Mouthon, L., Poiraudeau, S., Vernon, M., Papadakis, K., Perchenet, L., & Khanna, D. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-019-2087-4 · Cited by 24
Fleseriu, M., Molitch, M. E., Dreval', A. V., Pokramovich, Y. G., Бондарь, И. А., Poteshkin, Y. E., Μacut, D., Obermayer-Pietsch, B. M., Gilgun‐Sherki, Y., Haviv, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad365 · Cited by 24
Lombi, L., Alfieri, S., & Brunelli, C. (2023) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2023.102283 · Cited by 24
Zannad, F. M., Alikhaani, J. D., Alikhaani, S., Butler, J., Gordon, J. P., Jensen, K., Khatib, R., Mantovani, L. G., Martinez, R., Moore, W., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2828 · Cited by 24
Guan, Y., Puenpatom, A., Johnson, M. G., Zhang, Y., Zhao, Y., Surber, J., Weinberg, A. B., Brotons, C., Kozlov, R. S., Lopez, R., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad409 · Cited by 27
“…of a patient’s health condition that comes directly from the patient, are useful because they enhance the understanding of patients’ experiences with the study intervention Clinical Infectious Diseases M A J O R A R T I C L E compared with investigator-assessed or biomedical measures alone [9].”
BackgroundResultBasu, P. S., Mwanahamuntu, M., Pinder, L. F., Muwonge, R., Lucas, E., Nyambe, N., Chisele, S., Shibemba, A. L., Sauvaget, C., Sankaranarayanan, R., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03080-w · Cited by 23
“In this study, we included patient-reported outcomes to assess the impact of treatment from the patient’s perspective, which is increasingly being recognized by regulators, healthcare professionals and policy-making bodies as a valuable tool to collect patient-centered data 10 .”
MethodMaheta, B. J., Kraft, A., Interrante, N. R., Fereydooni, S., Bailenson, J. N., Beams, B., Keny, C., Osborne, T. F., Giannitrapani, K. F., & Lorenz, K. (2025) · Journal of Medical Internet Research · doi:10.2196/54452 · Cited by 26
“Functional outcomes are a useful adjunct to other quality of life–relevant measures to understand the impact of serious illness on a person’s life [8].”
What is the future of patient-reported outcomes in sickle-cell disease?
Singh, S. A., Bakshi, N., Mahajan, P., & Morris, C. R. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1830370 · Cited by 24
“gov registry with a more recent analysis in the Australian New Zealand registry (2005–2017) showing a rate of 45% [10,11].”
BackgroundMethodModi, N. D., Danell, N. O., Perry, R. N. A., Abuhelwa, A. Y., Rathod, A., Badaoui, S., McKinnon, R. A., Haseloff, M., Shahnam, A., Swain, S. M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100475 · Cited by 24
Klockgether, T., Synofzik, M., AGI working group on COAs and Registries, Alhusaini, S., Anheim, M., Antonijevic, I. A., Ashizawa, T., Bataller, L., Berard, M., Bertini, E., et al. (2023) · The Cerebellum · doi:10.1007/s12311-023-01547-z · Cited by 26
“…www. ataxia- study-group. net/ html/ about/ ataxi ascal es) • Patient’s global impression of change (PGI) (7-point Likert scale related to functional impairment due to ataxia compared to the situation one year ago) • SARA [15] (http:// www. ataxia- study-group. net/ html/ about/ ataxi ascal es)”
Whitehouse, K., Stifani, B. M., Duffy, J. M., Kim, C. R., Creinin, M. D., DePiñeres, T., Winikoff, B., Gemzell‐Danielsson, K., Blum, J., Sherman, R. B., et al. (2021) · Contraception · doi:10.1016/j.contraception.2021.07.004 · Cited by 23
Sandhu, A. T., Calma, J., Skye, M., Kalwani, N. M., Zheng, J., Schirmer, J., Din, N., Brown‐Johnson, C. G., Gupta, A., Lan, R., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069624 · Cited by 24
Tran, H. A., Mackensen, S. V., Abraham, A., Castaman, G., Hampton, K. K., Knöbl, P., Linari, S., Odgaard-Jensen, J., Neergaard, J. S., Stasyshyn, O., et al. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102476 · Cited by 21
“Patient-reported outcomes (PROs) are an important way of evaluating a patient ’ s health status, with information reported directly by the patient [1 – 3].”
BackgroundChemaly, N., Kuchenbuch, M., Teng, T., Marie, E., D'Onofrio, G., Lo Barco, T., Brambilla, I., Flege, S., Hallet, A., & Nabbout, R. (2024) · Epilepsia Open · doi:10.1002/epi4.12557 · Cited by 20
Gounder, M. M., Razak, A. R. A., Gilligan, A. M., Leong, H., Ma, X., Somaiah, N., Chawla, S. P., Martín‐Broto, J., Grignani, G., Schuetze, S. M., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0284 · Cited by 20
Visaggi, P., Ghisa, M., Vespa, E., Barchi, A., Mari, A., Pasta, A., Marabotto, E., de Bortoli, N., & Savarino, E. V. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s276869 · Cited by 20
“124 PRO measures complement histological findings in EoE, and prompt clinicians to tailor therapeutic approaches.”
BackgroundSymptom‐based scoring for haemorrhoidal disease: a systematic review
Jin, J. Z., Xia, W., Connolly, A., & Hill, A. G. (2020) · Colorectal Disease · doi:10.1111/codi.15253 · Cited by 20
Alkan, H., Yıldız, N., & Ardıç, F. (2020) · Archives of Rheumatology · doi:10.46497/archrheumatol.2020.7750 · Cited by 20
A systematic review assessing the quality of patient reported outcomes measures in dry eye diseases
Recchioni, A., Aiyegbusi, O. L., Rivera, S. C., Rauz, S., & Slade, A. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253857 · Cited by 22
Metadata
- Authors
- Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M.
- Affiliations
- The University of Sydney (AU)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Friedlander, Michael
- Venue
- Patient Related Outcome Measures
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 9
- Pages
- 353-367
- ISSN
- 1179-271X (ISSN-L)
- PMC
- PMC6219423
- OpenAlex
- W2899320385
- Cited by
- 659
- References
- 73
- Citations by year
- 2026: 77 · 2025: 129 · 2024: 138 · 2023: 88 · 2022: 85 · 2021: 75 · 2020: 54 · 2019: 12
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Related Outcome Measures (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- Australian Government
- National Institute for Health and Care Research
- University of Birmingham
- Cancer Australia
- Surgical Reconstruction and Microbiology Research Centre
- National Health and Medical Research Council
- Birmingham Biomedical Research Centre
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- patient-reported outcomes, clinical trial endpoints, missing data, protocol design, patient-centered outcomes, regulatory guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.